Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Fineline Cube Aug 26, 2026
Company Drug PIC

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

Fineline Cube Aug 26, 2026
Company PIC

WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs

Fineline Cube Aug 26, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Drug

Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials

Fineline Cube Feb 10, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...

Company Drug

CARsgen’s Allogeneic BCMA CAR-T Therapy Achieves sCR in First Patient

Fineline Cube Feb 10, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the first patient treated with its...

Company

Haisco Pharmaceutical Group Registers Delaware Subsidiary to Expand Global Operations

Fineline Cube Feb 10, 2025

Shenzhen-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the registration of a new...

Company Drug

Beijing Luzhu Submits BLA for LZ901 Herpes Zoster Vaccine to NMPA

Fineline Cube Feb 10, 2025

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a human vaccine and therapeutic biologics manufacturer, announced...

Company Drug Hospital

Hainan Boao Lecheng Pilot Zone Implements Baclofen Intrathecal Therapy

Fineline Cube Feb 10, 2025

The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica,...

Company Deals

Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs

Fineline Cube Feb 10, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in...

Policy / Regulatory

NMPA’s New Guidelines for Drug Registration Review

Fineline Cube Feb 10, 2025

A Look at the New Rules for Chemical and Biological Drug Filings in China:The Center...

Policy / Regulatory

Shanghai’s Three-Year Plan to Boost Elderly Care Quality

Fineline Cube Feb 10, 2025

A Comprehensive Look at Shanghai’s Efforts to Integrate Medical Care and Elderly Care:The Shanghai Civil...

Company Drug

NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer

Fineline Cube Feb 10, 2025

The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...

Policy / Regulatory

Tianjin Municipality Boosts Biopharmaceutical Industry with New Measures

Fineline Cube Feb 10, 2025

An In – Depth Look at Tianjin’s Efforts to Accelerate Medical Innovation and Gather Resources:The...

Company Drug

Hansoh Pharma’s Uplizna Receives Priority Review for IgG4-RD Treatment

Fineline Cube Feb 10, 2025

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

NMPA Seeks Public Feedback on Export Drug Manufacturing Rules

Fineline Cube Feb 10, 2025

An In – Depth Look at the New Draft Proposal for the Administration and Management...

Company Deals

VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally

Fineline Cube Feb 10, 2025

China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen...

Policy / Regulatory

China’s Drug Procurement Under Scrutiny: Addressing Quality Concerns and Policy Reforms

Fineline Cube Feb 10, 2025

An In – Depth Exploration of the Recent Survey on Bulk Drug Procurement in China...

Policy / Regulatory

In-Depth Analysis of NHSA’s DRG/DIP Payment Reforms: A Path to Streamlined Healthcare Management

Fineline Cube Feb 10, 2025

Comprehensive Overhaul of Payment SystemsThe National Healthcare Security Administration (NHSA) has unveiled a series of...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6017 Gains NMPA Approval for Herpes Zoster Study

Fineline Cube Feb 8, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...

Company Drug

Nuance Pharma’s Ohtuvayre Receives Regulatory Approval in Macau for COPD Treatment

Fineline Cube Feb 8, 2025

China-based Nuance Pharma announced that it has received regulatory approval in Macau for its Ohtuvayre...

Company

Regend Therapeutics’ Pulmovinci Receives FDA Orphan Drug Designation for IPF

Fineline Cube Feb 8, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that the US Food and Drug Administration...

Company Drug

Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment

Fineline Cube Feb 8, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval...

Company Drug

CanSino Biologics’ DTcP Vaccine for Infants Gains Priority Review in China

Fineline Cube Feb 8, 2025

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA)...

Posts pagination

1 … 262 263 264 … 712

Recent updates

  • NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
  • FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
  • FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
  • MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
  • WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Company Drug PIC

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.